Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Unternehmen & Branche
| Name | AVANOS MEDICAL, INC. |
|---|---|
| Ticker | AVNS |
| CIK | 0001606498 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,15 Mrd. USD |
| Beta | 1,05 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 701,200,000 | -72,900,000 | -1.57 | 1,073,700,000 | 778,200,000 |
| 2025-09-30 | 10-Q | 177,800,000 | -1,400,000 | -0.03 | 1,067,700,000 | 778,000,000 |
| 2025-06-30 | 10-Q | 175,000,000 | -76,800,000 | -1.66 | 1,039,000,000 | 776,300,000 |
| 2025-03-31 | 10-Q | 167,500,000 | 6,600,000 | 0.14 | 1,107,800,000 | 839,400,000 |
| 2024-12-31 | 10-K | 687,800,000 | -392,100,000 | -8.53 | 1,154,200,000 | 828,500,000 |
| 2024-09-30 | 10-Q | 170,400,000 | 4,300,000 | 0.09 | 1,656,200,000 | 1,229,700,000 |
| 2024-06-30 | 10-Q | 171,700,000 | 1,800,000 | 0.04 | 1,657,800,000 | 1,222,000,000 |
| 2024-03-31 | 10-Q | 166,100,000 | -900,000 | -0.02 | 1,661,300,000 | 1,227,900,000 |
| 2023-12-31 | 10-K | 673,300,000 | -61,800,000 | -1.32 | 1,692,400,000 | 1,236,300,000 |
| 2023-09-30 | 10-Q | 171,300,000 | -3,700,000 | -0.08 | 1,724,900,000 | 1,222,100,000 |
| 2023-06-30 | 10-Q | 169,400,000 | -68,100,000 | -1.46 | 1,666,700,000 | 1,234,800,000 |
| 2023-03-31 | 10-Q | 159,300,000 | -500,000 | -0.01 | 1,734,900,000 | 1,298,700,000 |
| 2022-12-31 | 10-K | 684,100,000 | 50,500,000 | 1.07 | 1,786,900,000 | 1,291,200,000 |
| 2022-09-30 | 10-Q | 172,300,000 | 15,700,000 | 0.33 | 1,775,200,000 | 1,263,500,000 |
| 2022-06-30 | 10-Q | 170,900,000 | 12,500,000 | 0.26 | 1,752,800,000 | 1,259,000,000 |
| 2022-03-31 | 10-Q | 197,400,000 | 5,400,000 | 0.11 | 1,766,500,000 | 1,262,800,000 |
| 2021-12-31 | 10-K | 587,000,000 | 6,300,000 | 0.13 | 1,603,600,000 | 1,270,600,000 |
| 2021-09-30 | 10-Q | 184,100,000 | -35,300,000 | -0.73 | 1,597,900,000 | 1,267,100,000 |
| 2021-06-30 | 10-Q | 186,400,000 | 38,500,000 | 0.79 | 1,683,300,000 | 1,301,700,000 |
| 2021-03-31 | 10-Q | 180,700,000 | -8,400,000 | -0.17 | 1,648,800,000 | 1,257,400,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-11-18 | Holbrook Kerr | Officer, SVP, Chief Commercial Officer | Open Market Sale | -100 | 11.01 | -1,100.50 | -0,8% | |
| 2025-11-18 | Holbrook Kerr | Officer, SVP, Chief Commercial Officer | Open Market Sale | -305 | 11.02 | -3,361.10 | -2,4% | |
| 2025-11-18 | Holbrook Kerr | Officer, SVP, Chief Commercial Officer | Open Market Sale | -761 | 11.01 | -8,378.61 | -6,1% | |
| 2025-11-18 | Holbrook Kerr | Officer, SVP, Chief Commercial Officer | Open Market Sale | -13,834 | 11.00 | -152,174.00 | -110,8% | |
| 2025-08-13 | BLACKFORD GARY | Director | Open Market Purchase | 20,000 | 10.98 | 219,500.00 | +159,8% | |
| 2025-08-13 | BLACKFORD GARY | Director | Open Market Purchase | 40,000 | 11.00 | 439,800.00 | +320,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.